Ramos C, Montaño E, Reyes-López A, Lemus F, Pacheco M, Hernandez G, Lemus A. Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk: Evaluación Económica de Lenalidomida (Revlimid®) Para el Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q de Riesgo Bajo/Intermedio-1. Grhta [Internet]. 2019 Nov. 11 [cited 2024 Nov. 21];4(1):133-40. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/387